Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer

Response to (K)RAS^G12C and EGFR Inhibition in a Patient With NRAS^G12C-Mutated Rectal Cancer

Research output: Contribution to journal › Case report › Contributed › peer-review

Lino Möhrmann - , National Center for Tumor Diseases Dresden, German Cancer Consortium (Partner: DKTK, DKFZ), Helmholtz-Zentrum Dresden-Rossendorf, German Cancer Research Center (DKFZ) (Author)
Ani Cuberi - , Institute and Polyclinic of Diagnostic and Interventional Radiology (Author)
Sascha Brückmann - , Institute of Pathology (Author)
Sebastian Stasik - , Department of Internal Medicine I (Author)
Lukas C. Heukamp - , Institute for Hematopathology Hamburg GmbH (Author)
Martin Bornhäuser - , Department of Internal Medicine I, National Center for Tumor Diseases Dresden (NCT/UCC) (Author)
Hanno Glimm - , Department of Internal Medicine I, National Center for Tumor Diseases Dresden, German Cancer Consortium (Partner: DKTK, DKFZ), Helmholtz-Zentrum Dresden-Rossendorf, German Cancer Research Center (DKFZ) (Author)
Gunnar Folprecht - , Department of Internal Medicine I, University Cancer Centre Dresden (Author)

Humans, Mutation, Rectal Neoplasms/drug therapy, ErbB Receptors/genetics, Membrane Proteins, GTP Phosphohydrolases/genetics